SonoThera's $125m Series B Heads Recent Biofinancings

SonoThera's $125m Series B heads recent biofinancings

Our latest roundup of financings in the biotech sector includes impressive rounds for SonoThera, Ethyreal, CeQur, and City Therapeutics.

SonoThera raises $125M for non-viral gene therapy approach

SonoThera has secured $125 million to take its ultrasound-based gene therapy technology into the clinic. The company is focused on two lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, and

CureDuchenne Invests in SonoThera to Advance Nonviral Gene Therapy Platform for Duchenne Muscular Dystrophy

SonoThera press releaseCureDuchenne is pleased to announce that it has invested in SonoThera, supporting the advancement of its targeted, ultrasound-mediated gene delivery technology focused on the delivery of full-length dystrophin. SonoThera’s approach is designed to address multiple key limitations of conventional AAV-delivered gene therapies such as restricted payload capacity (limited to the delivery of a micro-dystrophin gene), immune resp…